Finland· FI-REL-REL61499

Vyxeos liposomal

A cytarabine and daunorubicin product containing daunorubicin hydrochloride + cytarabine, registered in Finland by Orifarm Oy. The same ATC class is registered in 13 of our 19 countries.

ATC L01XY01

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedVyxeos liposomalATCL01XY01REGISTER NO.FI-REL-REL61499PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Cytarabine and daunorubicin is registered in 13 of 19 countries.

Countries holding a registration under ATC L01XY01 (cytarabine and daunorubicin), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 8 of them publish a price we can compare per daily dose

Cytarabine and daunorubicin · ATC L01XY01

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Daunorubicin hydrochloride + Cytarabine
Manufacturer
Orifarm Oy
Country
Finland (FI)
ATC code
L01XY01
ATC class
Cytarabine and daunorubicin
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 1

1 priced
  • fi_myyntilupa
    513941
    44 mg / 100 mg
    EUR 6366.35

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fedd2d3d-caef-4df7-8122-2911979dc63e
GET /v1/drugs/fedd2d3d-caef-4df7-8122-2911979dc63e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos",
  "route": "Laskimoon",
  "ddd_unit": null,
  "strength": "44 mg / 100 mg",
  "atc_label": "sytarabiini ja daunorubisiini",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/18/1308/001",
  "fimea_rel_id": "REL61499",
  "authorised_at": "2023-03-29"
}

See everything about cytarabine and daunorubicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.